As one of the most common metabolic diseases,type 2 diabetes(T2D)has become a public health concern with rising global prevalence.Corni fructus(CF),a traditional Chinese herb utilized for centuries as homologous medic...As one of the most common metabolic diseases,type 2 diabetes(T2D)has become a public health concern with rising global prevalence.Corni fructus(CF),a traditional Chinese herb utilized for centuries as homologous medicinal and food resources,has been widely used to treat glucose and lipid metabolism disorders.However,as a core active ingredient of CF,whether and how morroniside(MOR)improves T2D is still unclear.This study aimed to explore the pathways by which MOR ameliorates T2D in mice induced by high-fat diet(HFD)and low-dose streptozotocin through 16S rRNA gene sequencing.We found that MOR treatment significantly ameliorated body weight loss,hyperglycemia,hyperlipidemia and insulin resistance in T2D mice.In addition,MOR remarkably improved inflammation-and oxidative stress-driven hepatic and pancreatic injuries in the model mice.Mechanistically,MOR rehabilitated the dysregulated diversity and constitution of the gut microbiota in T2D mice,with significant changes in relative abundance in genus such as Lactobacillus,Lachnospiraceae_NK4A136_group,and Lachnospiraceae_UCG-006 which are believed to be highly correlated with serum parameters and insulin resistance in mice with T2D.Therefore,we infer that MOR improves T2D at least partially by maintaining the host microbiota homeostasis,and MOR may be a promising candidate for T2D treatment.展开更多
AIM:To investigate the effect of morroniside(Mor)on lipopolysaccharide(LPS)-treated iris pigment epithelial cells(IPE).METHODS:IPE cells were induced by LPS and treated with Mor.Cell proliferation was detected by cell...AIM:To investigate the effect of morroniside(Mor)on lipopolysaccharide(LPS)-treated iris pigment epithelial cells(IPE).METHODS:IPE cells were induced by LPS and treated with Mor.Cell proliferation was detected by cell counting kit(CCK)-8,apoptosis was detected by flow cytometry,the levels of tumor necrosis factor-α(TNF-α),interleukin(IL)-6,and IL-8 were measured by enzyme-linked immunosorbent assay(ELISA)kits,and the protein expression of TLR4,JAK2,p-JAK2,STAT3,and p-STAT3 was analyzed by Western blotting.In addition,overexpression of TLR4 and Mor treatment of LPS-stimulated IPE cells were also tested for the above indices.RESULTS:Mor effectively promoted the proliferation and inhibited the apoptosis of LPS-treated IPE cells.In addition,Mor significantly reduced the levels of TNF-α,IL-6,and IL-8 and significantly inhibited the expression of TLR4,p-JAK2,and p-STAT3 in LPS-treated IPE cells.The effect of Mor on LPS-treated IPE cells was markedly attenuated after overexpression of TLR4.CONCLUSION:These findings suggest that Mor may ameliorate LPS-induced inflammatory damage and apoptosis in IPE through inhibition of TLR4/JAK2/STAT3 pathway.展开更多
Conventional medicine-based Chinese herbal prescriptions,have fascinated much attention due to their extensive and unique diversity of biological effects without toxicity and/or adverse effects.Treatment with Hachimi-...Conventional medicine-based Chinese herbal prescriptions,have fascinated much attention due to their extensive and unique diversity of biological effects without toxicity and/or adverse effects.Treatment with Hachimi-jio-gan(Ba-Wei-Di-Huang-Wan in Chinese)improved the dysregulated levels of hyperglycemic condition-related oxidative stress generation,advanced glycation endproduct generation,and renal function parameters.These results indicate that Hachimi-jio-gan is a prospective therapeutic agent against the pathogenesis of diabetic nephropathy.Cornel iridoid glycosides and polyphenol are the active compounds of Corni Fructus,the active component of Hachimi-jio-gan,against kidney damage caused by diabetes.Additionally,major components of the Corni Fructus,morroniside and 7-O-Galloyl-D-sedoheptulose(GS)are considered to be important contributors to prevent and/or delay the onset of kidney damage caused by diabetes.Chief of all,GS is expected to be developed as a novel therapeutic drug for the diabetes-accelerated kidney damage.展开更多
基金supported by the Administration of Traditional Chinese Medicine Special Fund of Shaanxi Province(2021-QYZL-01,2021-QYZL-03)Special Funding for Basic Research Operating Expenses of the Central Universities(GK202205001,GK202205010)Hebei Province Innovation Capacity Enhancement Program Project(225A2501D).
文摘As one of the most common metabolic diseases,type 2 diabetes(T2D)has become a public health concern with rising global prevalence.Corni fructus(CF),a traditional Chinese herb utilized for centuries as homologous medicinal and food resources,has been widely used to treat glucose and lipid metabolism disorders.However,as a core active ingredient of CF,whether and how morroniside(MOR)improves T2D is still unclear.This study aimed to explore the pathways by which MOR ameliorates T2D in mice induced by high-fat diet(HFD)and low-dose streptozotocin through 16S rRNA gene sequencing.We found that MOR treatment significantly ameliorated body weight loss,hyperglycemia,hyperlipidemia and insulin resistance in T2D mice.In addition,MOR remarkably improved inflammation-and oxidative stress-driven hepatic and pancreatic injuries in the model mice.Mechanistically,MOR rehabilitated the dysregulated diversity and constitution of the gut microbiota in T2D mice,with significant changes in relative abundance in genus such as Lactobacillus,Lachnospiraceae_NK4A136_group,and Lachnospiraceae_UCG-006 which are believed to be highly correlated with serum parameters and insulin resistance in mice with T2D.Therefore,we infer that MOR improves T2D at least partially by maintaining the host microbiota homeostasis,and MOR may be a promising candidate for T2D treatment.
基金Supported by the Natural Science Foundation of Gansu Province(No.23JRRA0942)Innovation Fund for Colleges and Universities in Gansu Province(No.2021B-23).
文摘AIM:To investigate the effect of morroniside(Mor)on lipopolysaccharide(LPS)-treated iris pigment epithelial cells(IPE).METHODS:IPE cells were induced by LPS and treated with Mor.Cell proliferation was detected by cell counting kit(CCK)-8,apoptosis was detected by flow cytometry,the levels of tumor necrosis factor-α(TNF-α),interleukin(IL)-6,and IL-8 were measured by enzyme-linked immunosorbent assay(ELISA)kits,and the protein expression of TLR4,JAK2,p-JAK2,STAT3,and p-STAT3 was analyzed by Western blotting.In addition,overexpression of TLR4 and Mor treatment of LPS-stimulated IPE cells were also tested for the above indices.RESULTS:Mor effectively promoted the proliferation and inhibited the apoptosis of LPS-treated IPE cells.In addition,Mor significantly reduced the levels of TNF-α,IL-6,and IL-8 and significantly inhibited the expression of TLR4,p-JAK2,and p-STAT3 in LPS-treated IPE cells.The effect of Mor on LPS-treated IPE cells was markedly attenuated after overexpression of TLR4.CONCLUSION:These findings suggest that Mor may ameliorate LPS-induced inflammatory damage and apoptosis in IPE through inhibition of TLR4/JAK2/STAT3 pathway.
文摘Conventional medicine-based Chinese herbal prescriptions,have fascinated much attention due to their extensive and unique diversity of biological effects without toxicity and/or adverse effects.Treatment with Hachimi-jio-gan(Ba-Wei-Di-Huang-Wan in Chinese)improved the dysregulated levels of hyperglycemic condition-related oxidative stress generation,advanced glycation endproduct generation,and renal function parameters.These results indicate that Hachimi-jio-gan is a prospective therapeutic agent against the pathogenesis of diabetic nephropathy.Cornel iridoid glycosides and polyphenol are the active compounds of Corni Fructus,the active component of Hachimi-jio-gan,against kidney damage caused by diabetes.Additionally,major components of the Corni Fructus,morroniside and 7-O-Galloyl-D-sedoheptulose(GS)are considered to be important contributors to prevent and/or delay the onset of kidney damage caused by diabetes.Chief of all,GS is expected to be developed as a novel therapeutic drug for the diabetes-accelerated kidney damage.
